비고령 성인환자의 만성폐쇄성폐질환 약물사용 현황과 영향인자
Prescription Patterns and Factors Related to the Number of Medications in Chronic Obstructive Pulmonary Disease in Non-elderly Adults
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: This study is to investigate the prescription patterns and factors related to the number of medications treating chronic obstructive pulmonary disease (COPD) in patients under 65 years old according to GOLD guidelines. Methods: We retrospectively analyzed the medical records of patients aged 40-64 years with a diagnosis of COPD from January to March 2016. Patients were classified by combined assessment of COPD (grades A, B, C, D) using spirometry, exacerbation history, mMRC, and/or CAT results. We analyzed prescribed medications, treatment options and factors related to the numbers of COPD medications. Results: The total number of prescriptions were 251. About 35.5% of patients were classified as GOLD A, 34.2% as GOLD B, 17.1% as GOLD C and 13.2% as GOLD D. Inhaled bronchodilator was prescribed for 86.9% of patients and the most frequent COPD medication was longacting muscarinic antagonist (LAMA) followed by inhaled corticosteroids/long acting beta agonist (ICS/LABA). The majority of low risk patients (GOLD A/B) were prescribed a monotherapy with LAMA or LABA. For high risk patients (GOLD C/D), combination treatment with ICS+LAMA+LABA was mostly prescribed. The 21.2% of patients in GOLD D received systemic corticosteroid. The average number of medications per prescription was 3.7, and this number increased with increasing COPD grade, COPD duration and lung function reduction (FEV1, FEV1/FVC). Conclusion: Generally high adherence to GOLD guideline recommendations was reported. Given the progressive nature of the disease, results suggest that closer attention to respiratory symptoms for early detection, diagnosis, and appropriate treatment of COPD is warranted.
Abstract
Background: This study is to investigate the prescription patterns and factors related to the number of medications treating chronic obstructive pulmonary disease (COPD) in patients under 65 years old according to GOLD guidelines. Methods: We retrospectively analyzed the medical records of patients aged 40-64 years with a diagnosis of COPD from January to March 2016. Patients were classified by combined assessment of COPD (grades A, B, C, D) using spirometry, exacerbation history, mMRC, and/or CAT results. We analyzed prescribed medications, treatment options and factors related to the numbers of COPD medications. Results: The total number of prescriptions were 251. About 35.5% of patients were classified as GOLD A, 34.2% as GOLD B, 17.1% as GOLD C and 13.2% as GOLD D. Inhaled bronchodilator was prescribed for 86.9% of patients and the most frequent COPD medication was longacting muscarinic antagonist (LAMA) followed by inhaled corticosteroids/long acting beta agonist (ICS/LABA). The majority of low risk patients (GOLD A/B) were prescribed a monotherapy with LAMA or LABA. For high risk patients (GOLD C/D), combination treatment with ICS+LAMA+LABA was mostly prescribed. The 21.2% of patients in GOLD D received systemic corticosteroid. The average number of medications per prescription was 3.7, and this number increased with increasing COPD grade, COPD duration and lung function reduction (FEV1, FEV1/FVC). Conclusion: Generally high adherence to GOLD guideline recommendations was reported. Given the progressive nature of the disease, results suggest that closer attention to respiratory symptoms for early detection, diagnosis, and appropriate treatment of COPD is warranted.
참고문헌 (14)
- The Korean Academy of Tuberculosis and Respiratory Diseases, "COPD Guideline: updated in 2014. 1st ed", The Korean Academy of Tuberculosis and Respiratory Diseases, ~ (2014)
- Mathers CD, "Projections of global mortality and burden of disease from 2002 to 2030", PLoS Med, 3, pp.e442~ (2006)
- Hwayeon Park, "Prevalence of Chronic Obstructive Lung Disease in Korea Using Data from the Fifth Korea National Health and Nutrition Examination Survey", Korean Journal of Family Medicine, 36(3), pp.128~134 (2015), 대한가정의학회
- Yoo KH, "Prevalence of chronic obstructive pulmonary disease in Korea: the fourth Korean National Health and Nutrition Examination Survey, 2008", Respirology (Carlton, Vic.), 16, pp.659~665 (2011)
- Hogg JC, "The nature of small-airway obstruction in chronic obstructive pulmonary disease", N Engl J Med, 350, pp.2645~2653 (2004)
- Agustí A, "Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype", PLoS One, 7, pp.e37483~ (2012)
- Van Remoortel H, "Risk factors and comorbidities in the preclinical stages of chronic obstructive pulmonary disease", Am J RespirCrit Care Med, 189, pp.30~38 (2014)
- Kauppi P, "Overlap syndrome of asthma and COPD predicts low quality of life", J Asthma, 48(3), pp.279~285 (2011)
- Hardin M, "The clinical features of the overlap between COPD and asthma", Respir Res, 12, pp.127~ (2011)
- COPD based report 2010.ver1.1, "COPD clinical trial center", Korean Acad Tuberc resp dis, ~ (2010)
- Sin DD, "Mortality in COPD: Role of comorbidities", Eur Respir J, 28, pp.1245~1257 (2006)
- Donohue JF, "Once-Daily Bronchodilators for Chronic Obstructive Pulmonary Disease:indacaterol versus tiotropium", Am J Respir Crit Care Med, 182(2), pp.155~162 (2010)
- Decramer ML, "Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study", Lancet Respir Med, 1(7), pp.524~533 (2013)